Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial)

Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial)

Newly diagnosed multiple myeloma patients who are eligible for transplant usually receive several induction cycles of therapy, followed by one or two cycles of high-dose melphalan and autologous stem cell transfusion. In myeloma patients, high-dose melphalan improves overall survival and progression...

Full description

Saved in:
Bibliographic Details
Main Authors: Theo Leitner, Evgenii Shumilov, Christina Schwitlick, Raphael Koch, Franziska Hamm, Marion Högner, Florian Bassermann, Katja Weisel, Hermann Einsele, Martin Kortüm, Leo Rasche, Martin Görner, Kai Wegehenkel, Stefan Knop, Jan Krönke, Axel Nogai, Inke R. König, Maren Vens, Kay Horn, Nikolas von Bubnoff, Cyrus Khandanpour
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Hematology
Subjects:
newly diagnosed multiple myeloma
clinical trial
high-dose melphalan
autologous stem cell transfusion
isatuximab
MRD
Online Access:https://www.frontiersin.org/articles/10.3389/frhem.2024.1436845/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/frhem.2024.1436845/full

Similar Items